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Parkinson's disease (PD) is a neurodegenerative disease causing both motor and non-motor symptoms.
Drooling, an excessive pooling and spillover of saliva out of the oral cavity, is one of the non-motor
symptoms in PD patients that produces various negative physical and psychosocial consequences for
patients and their caregivers. At present, the pathophysiology of drooling in PD is not completely certain;
however, impaired intra-oral salivary clearance is likely the major contributor. There are neither standard
diagnostic criteria nor standard severity assessment tools for evaluating drooling in PD. In accordance
with the possible pathophysiology, dopaminergic agents have been used to improve salivary clearance;
however, these agents are not completely effective in controlling drooling. Various pharmacological and
non-pharmacological treatment options have been studied. Local injection with botulinum toxin sero-
types A and B into major salivary glands is most effective to reduce drooling. Future research to explore
the exact pathophysiology and develop standard diagnostic criteria and standard severity assessment
tools are needed to formulate speciﬁc treatment options and improve patient care.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Drooling may occur in many neurological disorders including
neuromuscular diseases such as myasthenia gravis, amyotrophic
lateral sclerosis (ALS) and oculopharyngeal muscular dystrophy,
neurodegenerative diseases such as Parkinson's disease (PD),
multiple system atrophy (MSA), progressive supranuclear palsy
(PSP), dementia with Lewy bodies (DLB) and corticobasal degen-
eration (CBD), and cerebrovascular diseases. Drooling is generally
deﬁned as excessive pooling and poor control of saliva in the oral8, Building 10, Room 7D37,
: þ1 301 480 2286.
allett@nih.gov (M. Hallett).
access article under the CC BY-NCcavity that might be caused by impaired salivary clearance whereas
sialorrhea refers to overﬂow or overproduction of saliva [1].
Regrettably, both terms are sometimes used interchangeably. If
patients have drooling, they might subsequently spill saliva from
their oral cavity, or might aspirate the saliva causing aspiration
pneumonia. Other possible negative consequences are poor oral
hygiene and social embarrassment. In PD, drooling is considered a
non-motor symptom. This article focuses on the prevalence, asso-
ciated factors, negative impacts of drooling, normal physiology of
salivation and swallowing, pathophysiology of drooling, assess-
ment tools, and treatment options for drooling in PD.
2. Methods
References for this reviewwere identiﬁed through searches of PubMed using the
search terms “Drooling and Parkinson's disease”, “Sialorrhea and Parkinson's-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Table 1
Prevalence of drooling in Parkinson's disease.
Year Reference Screening tools Number
surveyed
Prevalence
(%)
2012 Damian et al. [16] SCOPA-AUT 62 81
2012 Ozdilek et al. [15] UPDRS part II:
salivation subscore
50 84
2012 Rana et al. [14] UPDRS part II:
salivation subscore
307 40
2012 Perez-Lloret
et al. [13]
UPDRS part II:
salivation subscore
419 37
2011 Müller et al. [12] UPDRS part II:
salivation subscore
207 42
2010 Leibner et al. [11] Questionnaire:7-item
drooling survey
questionnaire
58 59
2008 Cheon et al. [10] PD-NMSQuest 74 32
2008 Nicaretta et al. [9] UPDRS part II:
salivation subscore
134 10
2007 MartinezeMartin
et al. [8]
PD-NMSQuest 525 42
2007 Verbaan et al. [7] SCOPA-AUT 420 73
2007 Kalf et al. [6] Questionnaire: “Do you
suffer from involuntary
loss of saliva (drooling)?’’
216 49
2002 Siddiqui et al. [5] Questionnaire: rating 0e4
point for detecting severity
of symptoms
44 52
0 ¼ normal
1 ¼ rare (one per month)
2 ¼ occasional
(one per week)
3 ¼ frequent (one per day)
4 ¼ constant
2002 Volonte et al. [4] Questionnaire: Present or
absent nocturnal sialorrhea
65 15
2000 Scott et al. [3] Questionnaire: present or
absent drooling
943 40
1991 Edwards et al. [2] Questionnaire: rating
0e4 point for detecting
severity of symptoms
96 70
0 ¼ normal
1 ¼ rare (one per month)
2 ¼ occasional
(one per week)
3 ¼ frequent (one per day)
4 ¼ constant
UPDRS: Uniﬁed Parkinson's Disease Rating Scale; SCOPA-AUT: Scales for Outcome in
Parkinson's disease; autonomic; PD-NMSQuest: Parkinson's disease non-motor
symptoms questionnaire.
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papers that were published between January 1973 to August 2014. Only reports
published in English were included. We cited references reﬂecting personal selec-
tion of the review authors.
3. Prevalence, associated factors and negative impacts of
drooling in PD
Due to the lack of a standard deﬁnition and criteria for diag-
nosing drooling in PD patients, estimates of prevalence vary. Pre-
vious studies showed that prevalence ranged from 10 to 84%
(Table 1) [2e16]. Various tools such as the Uniﬁed Parkinson's
Disease Rating Scale (UPDRS) part II [12e15]; Scales for Outcomes
in PD for Autonomic Symptoms (SCOPA-AUT) [7,16]; PD non-motor
symptoms questionnaire (PD-NMSQuest) [8,10]; and different
types of screening questionnaires [2e7,10,11] were used to screen
drooling. The factors associated with drooling have been reported.
However, results vary among studies and the conclusion remains
unclear. Factors possibly associated with drooling were severity of
PD [2,14], male gender [3,10], aging [6], hallucinations [11], duration
of PD [13], the sum of the scores of UPDRS part II and III greater than28 points, dysarthria, dysphagia, orthostatic hypotension, and a
history of using antidepressants [12]. Drooling during PD can have
negative impact for both patients and caregivers. Many negative
physical sequelae were reported to follow the course of drooling
such as perioral dermatitis, poor oral hygiene, bad breath, increased
amount of intra-oral occult bacteria, eating and speaking difﬁculty,
and an increased rate of respiratory tract infection from silent
aspiration of saliva [11,17e21]. Psychosocially, drooling PD patients
showed poor quality of life (QoL), i.e., social embarrassment and
increasing emotional distress [6,11]. In addition, drooling patients
affected their caregivers by increasing their burden, depression and
anxiety, and reducing their QoL [16].
4. Normal physiology of salivation and swallowing
The processes of salivation are controlled by both sympathetic
and parasympathetic nervous systems. However, facilitation of
ingestion and swallowing are mainly contributed by the para-
sympathetic nervous system. The parasympathetic afferent path-
ways receive unconditioned reﬂex stimulation from the pharynx
and esophagus. Then, signals are conducted via the vagus and
spinal splanchnic nerves to the salivary center located in the me-
dulla. The parasympathetic outputs are conducted via two different
pathways including the glossopharyngeal nerve, which then in-
nervates the otic ganglion, and, subsequently, to the parotid glands
via the auriculotemporal nerve and the facial nerve through the
chorda tympani nerve to the submandibular ganglia and then in-
nervates the submandibular and sublingual glands via the lingual
nerve [22].
The normal physiology of human swallowing is composed of
three phases: oral, pharyngeal, and esophageal. The oral phase is
voluntary whereas pharyngeal and esophageal phases are invol-
untary. When swallowing begins, the oropharyngeal phase uses
more than 30 different muscles to coordinate and precisely time
moving the food bolus to the esophagus. The upper esophageal
sphincter (UES) subsequently opens and the bolus passes through
the esophagus by peristalsis into the stomach [23]. The central
motor control areas include the premotor cortex, primary motor
cortex, basal ganglia, pedunculopontine nuclei, and cerebellum;
they project descending motor outputs to the medullary swallow-
ing center which includes a swallowing central pattern generator
and its interneurons such as the nucleus of the solitary tract. After
that, the medullary swallowing center provides the outputs to the
structures involved in the swallowing process such as the tongue,
larynx, pharynx, and upper esophagus. Lingual muscles are
controlled by the motor output of the hypoglossal nucleus while
laryngeal, pharyngeal and upper esophageal muscles are controlled
by motor output of the nucleus ambiguus [24]. The oropharyngeal
phase is most affected in PD patients.
5. Pathophysiology of drooling in PD
Drooling is more prominent during the “off” period. Two major
domains possibly inﬂuencing the pathophysiology of drooling in PD
have been proposed: one is an abnormality of salivary production
and the other is insufﬁcient salivary clearance. Overproduction of
saliva might cause drooling. However, many studies showed that
drooling PD patients produced less saliva compared to normal
controls [25e27]. The exact mechanisms causing decreased sali-
vary production are not understood [26]. A possible explanation is
dopamine deﬁciency. Previous studies in both invertebrate and
vertebrate animal models showed that dopamine modulates sali-
vary secretion [28,29]. Experimental studies in rats demonstrated
that activation of central and peripheral dopamine receptors pro-
duced salivary secretion [29]. Supportive evidence consists of
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which is the lateral mesencephalic reticular formation, could
signiﬁcantly decrease salivary secretion [30]. A pathological study
showed Lewy bodies in the superior cervical ganglion, cervical
sympathetic trunk, peripheral vagus nerve, and submandibular
glands [31]. Another study used Tc-99m scintigraphy to measure
the activity of salivary production and speed of salivary excretion of
the parotid glands in drooling PD patients compared to healthy
controls. The result showed that salivary production in drooling PD
patients and healthy controls was the same. However, the speed of
salivary excretion to a discrete stimulus in drooling PD patients was
signiﬁcantly higher compared to healthy controls [32]. According to
the above-cited evidence, increasing salivary production should not
be a main contributor to the pathophysiology of drooling in PD.
However, increasing speed of salivary excretion might partially
contribute to its pathophysiology.
Swallowing dysfunction in PD patients, in which the oropha-
ryngeal phase is amajor component, is the other domain thatmight
contribute to drooling. Oropharyngeal dysphagia in PD patients can
result from bradykinesia. A previous animal study showed that 6-
hydroxydopamine (6-OHDA) injected rat models exhibited slow
tongue protrusion speed and that average tongue press time was
signiﬁcantly longer compared to normal controls [33]. Another
study showed that the maximum tongue pressure in advanced PD
patients was lower compared to early or moderate PD patients, and
that oropharyngeal transit time was negatively correlated with
tongue movement speed [34]. Both studies reﬂect the fact that PD
patients have bradykinesia and poor muscle control of the tongue.
Therefore, dysfunction of the motor control of the tongue con-
tributes to the pathophysiology of dysphagia and, therefore, also
possibly drooling. A videoﬂuorographic study of 6-OHDA rat
models showed that the parkinsonian rat models had higher rates
of aberrant food bolus movement compared to normal controls
[35]. Another study using barium swallowwith videoﬂuoroscopy in
drooling PD patients demonstrated a direct correlation between
the severity of dysphagia and the severity of drooling [36]. There-
fore, oropharyngeal dysphagia might be a major contributor to the
pathophysiology of drooling in PD. In addition, upper esophageal
dysmotility might also affect dysphagia and drooling. The data from
previous manometric studies demonstrated evidence of impaired
UES relaxation in PD patients compared to normal controls. How-
ever, this factor cannot be the sole cause of dysphagia if patients
have sufﬁcient pharyngeal propulsive forces and clearance mech-
anisms [37,38].
In addition, a recent study showed that severe hypomimia,
unintentional mouth opening and stooped posture with dropped
head, could cause drooling in PD patients by losing the ability to
maintain saliva within the oral cavity [39]. In contrast, there is noFig. 1. Possible pathophysiology of dobvious evidence that medication-induced dyskinesia can produce
drooling. The possible domains contributing to the pathophysi-
ology of drooling in PD are summarized in Fig. 1.
6. Assessment tools for drooling in PD
The assessment tools to evaluate drooling in PD include both
objective and subjective measures. Objective tools were developed
tomeasure the volume of saliva and salivary ﬂow. The limitations of
these tools are that they are time-consuming and cannot evaluate
the psychosocial impairment. Therefore, subjective tools were
developed. The subjective measures in many previous studies were
the UPDRS part II salivary subscores to evaluate drooling treatment
responses and visual analog scales (VAS) to assess the frequency,
familial (VAS-FD) and social distress (VAS-SD); however, not all
scales are validated. Three drooling-speciﬁc rating scales including
the Drooling Severity and Frequency Scale (DSFS), Drooling Rating
Scale (DRS) and Sialorrhea Clinical Scale for PD (SCS-PD) have been
used to evaluate drooling in PD. The DSFS, a semi-quantitative scale,
was used in studies to evaluate drooling in PD and cerebral palsy
(CP). The scale is composed of two domains: (a) the severity of
drooling rated on a ﬁve-point scale and (b) frequency of drooling
rated on a four-point scale. Since the DSFS is easy to administer it is
widely used. However, the limitations of this scale are no assess-
ment of the psychosocial impact, no validation and no evidence of
correlation between this scale and the objective measures of sali-
vary secretion.
With the DRS, patients are rated for severity of drooling by 0e3
points. The DRS is scored for the preceding week while sitting,
standing, staying in bed, talking, and eating or drinking. The ad-
vantages of this scale are ease of use and evaluation of drooling in
various situations, but the limitation is the lack of psychosocial
evaluation. The SCS-PD was developed to cover social and func-
tional impairment with respect to the severity and frequency of
drooling. Patients rate a score from 0 to 3 points per question for
seven questions covering the severity, frequency and feeling of
discomfort during day-time, night-time, eating, speaking and social
participation within the preceding week. The two advantages of
this scale are coverage of the social and functional impairment and
also validation using saliva volume measurements in PD patients
and healthy volunteers. This scale was originally made and vali-
dated in Spanish and then translated into English. Therefore, the
language translation might be an important factor contributing to
measurement bias.
Recommendations from theMovement Disorders Society (MDS)
do not specify which rating scale should be the standard subjective
tool. However, they suggest that all three rating scales can be used
to evaluate drooling in PD patients [40].rooling in Parkinson's disease.
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ment of swallowing function especially in the oropharyngeal phase.
Earlier Nilsson et al. [41] used the ROSS test to measure the peak
suction pressure, suction time, bolus volume, and oral-pharyngeal
transit time; however, this test has some limitations such as
complexity and inability to visualize the process. At present, vid-
eoﬂuoroscopic examination is the most common method for
evaluation of swallowing disorders, andmany studies [42e44] have
used this tool to assess swallowing function. The advantage of this
tool are real-time visualization and more details in terms of onset
and offset of oral transit time and pharyngeal transit time, number
of tongue pumps while the bolus is in the oral cavity, and rating the
penetration-aspiration scale.
7. Treatment options for drooling in PD
First, treatment should begin by withdrawing medications that
aggravate drooling such as cholinesterase inhibitors, clozapine or
quetiapine. Next, the target might be to improve motor symptoms
by using dopaminergic medications or by performing deep brain
stimulation if the motor symptoms otherwise justify these ap-
proaches. However, the response of drooling is usually only partial
and there is clearly a need for a speciﬁc adjunctive treatment for
this problem. Speciﬁc treatment options for drooling in PD are both
pharmacological and non-pharmacological.
7.1. Pharmacological treatments
The groups of medications that have been studied are anticho-
linergics, adrenergic receptor antagonists, and botulinum neuro-
toxin (BoNT), both serotypes A (BoNT-A) and B (BoNT-B).
Paragraphs below and Table 2 summarize the evidence and current
recommendations of pharmacological treatment options for
drooling in PD.
7.1.1. Anticholinergics
Blocking cholinergic receptors, especially subtype M3, can
minimize salivary secretion. Therefore, anticholinergics can be
used to reduce drooling. However, because available agents are
not selective for M3 receptors, they might produce undesirable
adverse effects such as confusion, hallucinations, constipation,
urinary retention, and drowsiness. Sublingual atropine, sublin-
gual ipratropium bromide spray, oral glycopyrrolate and intra-
oral tropical tropicamide were studied in drooling patients with
PD whereas oral trihexyphenidyl, benztropine and transdermal
scopolamine have not been. In an open-labeled pilot study using
sublingual atropine in 6 drooling PD and 1 drooling PSP patients,Table 2
Potential medications commonly used for treating drooling in Parkinson's disease.
Medication Mechanism of action
Glycopyrrolate [47] Anticholinergic: blocks muscarinic acetylcholine rec
unable to cross bloodebrain barrier
Ipratropium bromide [46] Anticholinergic: muscarinic cholinergic receptor ant
without speciﬁcity for subtypes; unable to cross blo
Atropine [45] Anticholinergic: competitive inhibitor of muscarinic
receptors; crossing bloodebrain barrier
Clonidine [52] a-2 adrenergic receptor agonist
Modaﬁnil [52] a-1 adrenergic receptor agonist
OnabotulinumtoxinA [53e59] Reducing presynaptic acetylcholine release
AbobotulinumtoxinA [60e62] Reducing presynaptic acetylcholine release
RimabotulinumtoxinB [63e67] Reducing presynaptic acetylcholine releaseresults showed that 1 drop of 1% atropine solution twice daily for
a 1-week period demonstrated a statistically signiﬁcant decline in
salivary production both objectively using the changing weight of
dental rolls after placing intra-orally for 5-min before and after
receiving treatment, and subjectively using self-reported drooling
severity, rating score from 1 (normal) to 5 points (severe).
Adverse events occurred in 3 patients: 1 with delirium and 2
with hallucinations [45].
A study of administering sublingual ipratropium bromide
was conducted in a 5-week, randomized double-blind, placebo-
controlled, cross-over study to assess efﬁcacy and safety in 17
PD patients with bothersome drooling. The primary outcome
was the changing weight of cotton rolls before and after
receiving treatment. Secondary outcomes were subjective rat-
ings of the severity and frequency of drooling using home di-
aries, UPDRS part II salivation subscores, parkinsonian disability
using UPDRS, and adverse events. The results showed no sig-
niﬁcant difference in objective measurement at the end of 2
weeks of treatment with ipratropium bromide compared to
placebo. However, there was a mild effect on the subjective
measurement. In addition, there were no signiﬁcant differences
in the number of adverse events between the ipratropium
bromide and placebo groups [46].
A 4-week, randomized, double-blind, placebo-controlled cross-
over trial with 1 mg of oral glycopyrrolate administered three-
times daily in 23 drooling PD patients was conducted. Change in
sialorrhea scoring scale (SSS) scores in terms of a greater than 30%
improvement was assessed. The difference in the means of SSS
scores between the placebo and glycopyrrolate groups was a sec-
ondary outcome. The results were statistically signiﬁcant in both
primary and secondary outcomes (p ¼ 0.021 and p ¼ 0.011,
respectively). There were no statistically signiﬁcant differences in
adverse events between the treatment and placebo groups [47].
The efﬁcacy and safety of intra-oral tropical tropicamide was
studied in 12 drooling PD patients. Results showed no signiﬁcant
improvement of VAS between placebo and treatment groups for
each dose without any adverse events [48].
In conclusion, according to the current recommendations of
MDS for treating drooling in PD with anticholinergics, glyco-
pyrrolate is efﬁcacious, but there is lack of evidence for treating
longer than 1 week. There are insufﬁcient data regarding its safety.
There is not enough information about the efﬁcacy and safety of
ipratropium bromide spray to treat drooling [49].
7.1.2. Adrenergic receptor agonists
The effect of a-2 adrenergic receptors might partially contribute
to drooling. Clozapine and yohimbine, a-2 adrenergic receptorDose Route of
administration
eptor; 1e2 mg twice or three-times daily Oral
agonist
odebrain barrier
21 mg four-times daily Sublingual spray
acetylcholine 0.5 mg twice daily Sublingual drop
0.15 mg daily Oral
100 mg daily Oral
5-50 units per each parotid gland
5 units per each submandibular gland
Local injection
75e146.2 units per each parotid gland
78.7 units per each submandibular gland
Local injection
500-2000 units per each parotid gland
250 units per each submandibular gland
Local injection
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effect [50,51]. Therefore, activation of a-2 adrenergic receptors
might reduce drooling. Clonidine improved drooling in a small
randomized, double-blinded, placebo-control study in 32 drooling
PD patients. Seventeen subjects were treated with clonidine and 15
received placebo. The assessment tool measured how many times
each subject had to clear their saliva in a 5-min period. Evaluation
was performed at baseline, 1 and 3 months after randomization.
Results showed that clonidine signiﬁcantly improved the number
of times of clearing saliva at both time periods [52]. Oral modaﬁnil
100 mg daily was reported to be beneﬁcial for drooling in patients
with PD. However, modaﬁnil is an a-1 receptor agonist; therefore,
the reduced drooling might be related to the improvement of
dysphagia rather than hypersalivation [52]. The efﬁcacy of mod-
aﬁnil needs further investigation.
In conclusion, there are no current recommendations for using
adrenergic receptor agonists to treat drooling in PD. However,
clonidine and modaﬁnil might be considered according to the re-
sults of previous small studies.
7.1.3. Botulinum toxin injection
The mechanism of action of BoNT is inhibition of acetylcholine
release. Two serotypes, BoNT-A and BoNT-B, were studied in
drooling PD patients. Results after local injection of BoNT into the
salivary glands are inhibition of cholinergic parasympathetic and
postganglionic sympathetic activity causing reduction of salivary
secretion. Studies of both BoNT-A and BoNT-B are summarized in
Table 3.
Two types of BoNT-A, onabotulinumtoxinA and abobotuli-
numtoxinA, have been used to treat drooling in PD. Seven studies
including 1 case series [53], 3 open-label studies [54e56], 1 open-
labelled caseecontrol study [57], 1 randomized placebo-control
study [58] and 1 randomized, double-blinded, placebo-control
study [59] used onabotulinumtoxinA for treating drooling patients
with PD. OnabotulinumtoxinA was injected into the parotid glands
for all studies. One study included MSA and DLB patients whose
submandibular glands were injected [55]. No studies compared
injection of the parotid glands with the submandibular glands. Five
studies used a blind injection technique [53e55,57,59] whereas 2
studies used ultrasound guidance [56,58]. Santamato et al. con-
ducted an open-label study using ultrasound-guided toxin injec-
tion in 18 drooling PD patients while Dogu et al. conducted a
randomized control study comparing toxin injection in 15 drooling
PD patients divided into arms using (n ¼ 8) and not-using (n ¼ 7)
ultrasound guidance. In terms of pre- and post-treatment evalua-
tion, 2 studies only used subjective assessment [53,56], 1 only used
objective assessment [57], and 4 used both subjective and objective
assessment [54,55,58,59]. The subjective assessment tools included
reporting from patients and their spouses, DSFS and VAS for
drooling severity, frequency, VAS-FS and VAS-SD. The objective
assessment was the percent change of weight of dental roll after
placement in the mouth for 2, 5 or 10 min. Duration of evaluation
after start of treatment ranged from 1 to 16 weeks. All studies
agreed that onabotulinumtoxinA injection, dosage ranging from 5
to 50 units and 5 units per parotid and submandibular gland,
respectively, signiﬁcantly reduced drooling in PD, MSA and DLB
patients and improved subjective or objective assessments for
approximately 4 months. In addition, injecting the toxin under
ultrasound guidance might have provided more accuracy and more
reduction in salivary production compared to the blind injection
technique.
AbobotulinumtoxinA was also studied in drooling PD patients.
Three studies including 1 case series [60] and 2 randomized
double-blind, placebo-control studies [61,62] were published.
AbobotulinumtoxinA was injected into the parotid glands for allstudies. The study conducted by Lipp et al. included ALS, MSA and
CBD patients [61]. The study conducted by Mancini et al. included
MSA and injected submandibular glands [62]. Only one study used
a blind injection technique [61] whereas 2 studies used ultrasound
guidance [60,62]. Nobrega et al. reported a case series of abobo-
tulinumtoxinA injection under ultrasound guidance in 21 drooling
PD patients while Mancini et al. conducted a randomized, double-
blinded, placebo-control study using ultrasound-guided toxin in-
jection in 20 drooling patients (14 with PD and 6withMSA) divided
into 2 groups of 10 patients, treatment or placebo. These studies
conducted by Nobrega et al. and Mancini et al. used DSFS as a
subjective assessment while a study conducted by Lipp et al. used
percent change of weight of dental rolls after placing in the mouth
for 5-min as an objective assessment and a mechanical counter for
spitting in a 12 h period as a semi-objective assessment. Duration of
evaluation from start of treatment ranged from 1 to 4 weeks. All
studies agreed that abobotulinumtoxinA injection, with doses
ranging from 75 to 146.2 units and 78.7 units per parotid and
submandibular gland, respectively, signiﬁcantly reduced drooling
in PD, ALS, MSA and CBD patients in terms of either improved
subjective or objective assessments. This effect lasted for 1e4
months. In addition, a previous study conducted by Kalf et al.
showed no statistically signiﬁcant difference between parotid and
submandibular gland injection with abobotulinumtoxinA.
RimabotulinumtoxinB, the only available BoNT-B, has also
been studied in drooling PD patients. To date, 5 studies using
rimabotulinumtoxinB to treat drooling PD patients including 2
open-label studies [63,64] and 3 randomized double-blind, pla-
cebo-control studies [65e67] were published. Rimabotuli-
numtoxinB was injected into the parotid glands for all studies.
The study conducted by Contarino et al. included ALS patients.
Three studies also injected submandibular glands [64,65,67]. Four
studies used a blind injection technique [63,65e67] whereas 2
studies used ultrasound guidance [61]. The subjective assessment
tools used in the studies included DSFS, VAS for drooling severity,
VAS-FS, VAS-SD and DRS while the objective assessment was
percent change of weight of dental rolls after placing in the
mouth for 5-min. Duration of evaluation from start of treatment
ranged from 1 to 4 weeks. All studies agreed that rimabotuli-
numtoxinB injection in doses ranging from 500 to 2000 units and
250 units per parotid and submandibular gland, respectively,
signiﬁcantly reduced drooling in PD and ALS patients in terms of
improved subjective or objective assessments. This effect lasted
up to 4.8 months.
Guidubaldi et al. conducted a randomized, double-blinded,
placebo-controlled cross-over study comparing between BoNT-A
and B injection in 27 drooling patients (15 with ALS and 12 with
PD) under ultrasound guidance. Parotid gland was injected with
either 100 units of abobotulinumtoxinA or 1000 units of rimabo-
tulinumtoxinB while the submandibular gland was injected with
either 25 units of abobotulinumtoxinA or 250 units of rimabotuli-
numtoxinB. All patients were evaluated by DSFS, VAS, DRS and by
change of weight of dental roll after placing in the mouth for 5-min
at baseline, 1 and 4 weeks, and every 4 weeks until no beneﬁt was
observed. At 1 month, BoNT-B showed improvement in DSFS and
DRS more than BoNT-A; however, there were no signiﬁcant dif-
ferences between groups at 2 months [68].
In conclusion, as conﬁrmed in the current recommendations of
the MDS, both BoNT-A and BoNT-B are efﬁcacious for symptomat-
ically controlling drooling in PD [49]. Onset of effect of both BoNT-A
and B starts at 1 week, and lasts for approximately 3e5 months
after injection. Injecting BoNT-A or B under ultrasound guidance
might provide more beneﬁt; no obvious evidence showed a sig-
niﬁcant difference in term of efﬁcacy between BoNT-A and B. The
common adverse effect after injecting BoNT is dryness of mouth
Table 3
Studies of botulinum neurotoxin A and B for treating drooling patients with Parkinson's disease.
Study Type of study Type of BoNT Number of cases Dose (units per each
side)
USG Outcome
measurements
Results Adverse effects
Jost et al., 1999 [53] Case series OnabotulinumtoxinA 5 5 units per each parotid
gland
No Rating by the patient
and his or her spouse
2with good (normal salivation),
2 with moderate (decreased
salivation), 1 with no change
No
Pal et al., 2000 [54] Open-label OnabotulinumtoxinA 9 7.5 units then, 8 weeks
later 15 units per each
parotid gland
No DSFS and weight of
dental rolls placed in
the mouth for 5 min
8 patients had signiﬁcant
reduction of objective saliva
production. Approximately 35%
reduction in mean value of
salivary production at the end
of study
Dryness of mouth
Su et al., 2006 [55] Open- label OnabotulinumtoxinA 15 15 units for each
parotid gland and 5 unit
per each
submandibular gland
No DSFS and weight of
dental rolls placed in
the mouth for 10 min
Signiﬁcant reduction in
objective saliva production at 4
weeks (p < 0.01) and
improvement of DSFS score.
Dryness of mouth
Santamato
et al., 2008 [56]
Open- label OnabotulinumtoxinA 18 15 units for each
parotid gland
Yes DSFS Signiﬁcant improvement of
DSFS at 4 weeks
No
Friedman
et al., 2001 [57]
Open label,
caseecontrol
OnabotulinumtoxinA 11 5 units per each parotid
gland
No Weight of dental rolls
placed in the mouth for
2 min
Signiﬁcant reduction in saliva
production at 1 week
(p < 0.0001 vs baseline)
No
Dogu
et al., 2004 [58]
Randomized
placebo-control
OnabotulinumtoxinA 15 30 units for each
parotid gland; 7 with
and 8 without
ultrasound guidance
Yes VAS and weight of
dental rolls placed in
the mouth for 5 min
Signiﬁcant reductions in saliva
production at 1, 4 and 12 weeks
(p ¼ 0.001 vs. baseline) in
ultrasound guidance group and
signiﬁcant reductions from
baseline in VAS scores.
Dryness of mouth
Lagalla
et al., 2006 [59]
Randomized
double-blind,
placebo-control
OnabotulinumtoxinA 16 with treatment and
32 with placebo
50 units per each
parotid gland
No VAS for drooling
frequency, VAS-FD,
VAS-SD and weight of
dental rolls placed in
the mouth for 5 min
Signiﬁcant reduction in
objective saliva production,
VAS for drooling frequency,
VAS-FD and VAS-FS at 4 weeks
Transient
swallowing
difﬁculty
Nobrega
et al., 2006 [60]
Case series AbobotulinumtoxinA 21 125 units per each
parotid gland
Yes DSFS Signiﬁcant Improvement of
DSFS at 4 weeks
Dryness of mouth
Lipp et al., 2003 [61] Randomized
double-blind,
placebo-control
AbobotulinumtoxinA 32 (20 with PD, 12 with
ALS); 7 with placebo, 8
with 18.7 units, 9 with
37.5 units and 8with 75
units group
18.7, 37.5, or 75 units
per each parotid gland
No 6-item questionnaire,
weight of dental rolls
placed in the mouth for
5 min and mechanical
counter once a week for
a 12-h
Saliva reduction of 50% and
signiﬁcant improvement of
counter measurement in group
treated with 75 units
No reported
Mancini
et al., 2003 [62]
Randomized
double-blind,
placebo-control
AbobotulinumtoxinA 20 (14 with PD, 6 with
MSA); 10 with placebo
and 10 with treatment
group
146.2 units per each
parotid gland and 78.7
units per each
submandibular gland
Yes DSFS Signiﬁcant reduction in DSFS at
1 week (p ¼ 0.005 vs placebo)
No
Racette
et al., 2003 [63]
Open- label RimabotulinumtoxinB 9 1000 units per each
parotid gland
No VAS and weight of
dental rolls placed in
the mouth for 5 min
Signiﬁcant improvement of VAS
score (P < 0.001)
Transient dryness
of mouth
P.Srivanitchapoom
et
al./
Parkinsonism
and
Related
D
isorders
20
(2014)
1109
e
1118
1114
Contarino
et al., 2007 [64]
Open- label RimabotulinumtoxinB 9 1000 units per each
parotid gland and 250
units per each
submandibular gland
Yes DSFS, VAS and weight
of dental rolls placed in
the mouth for 5 min
Signiﬁcant reduction of
objective saliva production at 1
week and signiﬁcant
improvement of DSFS and VAS
score at 1 week.
Dryness of mouth
Ondo
et al., 2004 [65]
Randomized
double-blind,
placebo-control
RimabotulinumtoxinB 16; 8 with placebo and
8 with treatment group
1000 units per each
parotid gland and 250
units per each
submandibular gland
No DSFS, VAS and DRS Signiﬁcant improvement of
DSFS (p < 0.001), VAS
(p < 0.001) and DRS (p < 0.05)
Dryness of mouth,
worsening gait
difﬁculty, neck pain
and diarrhea
Lagalla
et al., 2009 [66]
Randomized
double-blind,
placebo-control
RimabotulinumtoxinB 36; 18with placebo and
18 with
treatment group
Total dose 4000 units
per bilateral parotid
glands
No DSFS, VAS-FD, VAS-SD
and weight of dental
rolls placed in the
mouth for 5 min
Signiﬁcant reduction of
objective salivary production at
4 weeks (p < 0.0001) and
signiﬁcant improvement Of
DSFS, VAS-FD and VAS-SD
Transient
dysphagia and
transient weakness
of chewing
Chinnapongse
et al., 2012 [67]
Randomized
double-blind,
placebo-control
RimabotulinumtoxinB 54; 15 with placebo, 14
with
1500 units, 12 with
2500 units
and 13 with 3500 units
group
Placebo, 500, 1000,
1500 units per each
parotid gland and
placebo and ﬁxed dose
250 units per each
submandibular gland in
treatment group
No Investigator: DSFS, CGI,
UPDRS part II;
salivation and
swallowing subscore
All subjective evaluation by
both investigator and subject
signiﬁcantly improved at 4
weeks comparing to baseline
Dryness of mouth
and viscous saliva
Subject: DSFS, PGI,
UPDRS part II;
salivation and drooling
impact scale
Guidubaldi
et al., 2011 [68]
Randomized
double-blind,
cross-over
AbobotulinumtoxinA and
RimabotulinumtoxinB
27 (12 with PD and 15
with ALS);
13 with BoNT-A and 14
with
BoNT-B group
AbobotulinumtoxinA:
100 units per each
parotid gland and 25
units per each
submandibular gland
Yes DSFS, VAS, DRS and
weight of dental rolls
placed in the mouth for
5 min
Latency: Signiﬁcantly shorter
after BoNT-B (3.2 ± 3.7 days)
than that after BoNT-A
(6.6 ± 4.1 days; P ¼ 0.002)
Dryness of mouth
and viscous saliva
RimabotulinumtoxinB:
1000 units per each
parotid gland and 250
units per each
submandibular gland
1 week: BoNT-B treatments
reduced the cotton roll weights
more than that of BoNT-A
(P ¼ 0.024) and slightly better
subjective scales than BoNT-A
1 month: BoNT-B slightly better
subjective scales than BoNT-A
2 months: No signiﬁcant
differences between BoNT-A
and B in both objectively and
subjectively measurements
ALS: Amyotrophic lateral sclerosis; BoNT: Botulinum neurotoxin; CGI: Clinician global impression; DSFS: Drooling Severity and Frequency Scale; DRS: Drooling Rating Scale; MSA: Multiple system atrophy; PGI; Patient global
impression; VAS: Visual analog scale; VAS-FD: Visual analog scale for familial distress; VAS-SD: Visual analog scale for social distress; UPDRS: Uniﬁed Parkinson's Disease Rating Scale; USG: Ultrasound guidance.
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Fig. 2. Landmark for injecting parotid and submandibular gland.
P. Srivanitchapoom et al. / Parkinsonism and Related Disorders 20 (2014) 1109e11181116which is generally mild. The anatomical landmarks for injecting the
parotid and submandibular glands are in Fig. 2.
7.2. Non-pharmacological treatments
Many non-pharmacological approaches such as chewing gum,
behavioral modiﬁcation, radiotherapy (RT) and surgical treatment
were reported. However, only 2 studies mainly involving PD pa-
tients were published [69,70]. Mark et al. conducted a randomized
placebo-control study involving 6 PD patients to evaluate the effect
of behavioral modiﬁcation. Patients were instructed to consciously
swallow their saliva each time when they heard the sound. Results
showed a signiﬁcant reduction of DRS; however, the magnitude of
effect decreased at 3 months compared to 1 month. The authors
concluded that self-motivation was important in increasing the
beneﬁt with this intervention [69]. Postma et al. reported a case
series of 28 drooling patients (22 with PD, 1 with vascular parkin-
sonism, 3 with MSA and 2 with PSP) who received a bilateral 12 Gy
of RT to the parotid and superior parts of the submandibular glands
to reduce drooling. The authors used UPDRS part II salivation
subscore and shortened Parkinson's Disease Questionnaire-8 for
evaluating efﬁcacy of treatment and QoL, respectively, at pre-RT, 1
and 6 months post-RT. Drooling improved signiﬁcantly at 1 month
post-RT and this effect lasted for 1 year. Common adverse events
were loss of taste and dry mouth; however, 75% of these adverse
events were transient. QoL improved signiﬁcantly in the long term
[70]. To date, there is no study that particularly investigated the
effect of deep brain stimulation (DBS) on drooling in PD patients. To
the extent that drooling is caused by a swallowing problem, if DBS
affected swallowing, there could be an inﬂuence on drooling. A
systematic review showed no effect of DBS on swallowing [71], but
a recent result showed a deleterious effect with unilateral sub-
thalamic nucleus DBS [72]. It seems unlikely that DBS will help
drooling.
In conclusion, there are no current recommendations for using
non-pharmacological treatments to treat drooling in PD. However,
behavioral modiﬁcation and, in refractory cases, RT might be
considered as an adjunctive therapy.
8. Conclusion
Drooling produces important negative consequences for both
PD patients and their caregivers. While the main problem seems to
be failure of swallowing, most of the treatments are directed to
reducing salivary secretion. At present, local injection with BoNT
into major salivary glands is the most effective therapeutic option.
There are some areas of uncertainty that need further research
including addressing the pathophysiology and standardizingdiagnostic criteria and severity assessment tools. Developing more
speciﬁc therapeutic options would be valuable to improve patients'
quality of life.
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